Compound ID | 2978

Update compound information

VXc-486 (prodrug pVXc-486)

Class: DNA synthesis inhibitor

Agent Type: Synthetic; Small molecule; Direct acting;
Spectrum of activity: Antimycobacterial
Mechanism of action: DNA synthesis inhibitor. Gyrase B inhibitor
Target Pathogen: Active against Mycobacterium tuberculosis, Mycobacterium abscessus, Mycobacterium avium complex, and Mycobacterium kansasii
Description: Synthetic compound; aminobenzimidazole; active against Mycobacterium tuberculosis within macrophages; prodrug has improved solubility rapidly converted to active compound
Institute where first reported: Vertex Pharmaceuticals Incorporated, Boston, Massachusetts, USA
Year first mentioned: 2015
Development status: Experimental
Chemical structure(s):
Click here for structure editor
Molecular weight: 428.46
Iso. SMILES: CCNC(=O)NC1=NC2=C(N1)C=C(C(=C2[C@H]3CCCO3)F)C4=CN=C(N=C4)C(C)(C)O
InChI Key: BKUISYCLLXCBJV-CQSZACIVSA-N
Can. SMILES: CCNC(=O)NC1=NC2=C([C@H]3CCCO3)C(=C(C=C2N1)C4=CN=C(C(C)(C)O)N=C4)F
InChI: InChI=1S/C21H25FN6O3/c1-4-23-20(29)28-19-26-13-8-12(11-9-24-18(25-10-11)21(2,3)30)16(22)15(17(13)27-19)14-6-5-7-31-14/h8-10,14,30H,4-7H2,1-3H3,(H3,23,26,27,28,29)/t14-/m1/s1
External links:
PubChem link: https://pubchem.ncbi.nlm.nih.gov/compound/57524959
Guide to Pharmacology: SPR719
Citations:
  • https://pubs.acs.org/doi/10.1021/jm800318d
  • https://journals.asm.org/doi/10.1128/aac.00596-06
  • https://journals.asm.org/doi/10.1128/aac.04347-14

    • AntibioticDB is supported by GARDP.

    If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions

    The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.